Funding for this research was provided by:
Public Health Agency of Canada (PSO-PHAC-10313-R11)
Text and Data Mining valid from 2019-01-19
Received: 29 August 2018
Accepted: 20 December 2018
First Online: 19 January 2019
Ethics approval and consent to participate
: Not applicable.
: Written informed consent to publish was obtained from the stakeholders who provided feedback on the protocol. A copy of the written consent is available for review by the Editors-in-Chief of this journal. The stakeholder feedback has been anonymized and included as Additional file InternalRef removed.
: BH has received consultancy fees from Cornerstone Research Group for methodologic advice related to systematic reviews and meta-analysis and is a member of the Editorial team for <i>Systematic Reviews</i>. PS reports grants and research support from Pfizer Inc., Bhasin Consulting Fund, and Patient Centered Outcomes Research Institute; consulting fees from Pfizer Canada Inc., Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, NVision Insight Group, and Myelin & Associates; receival of drugs free of charge or at a discounted rate for study through open tender process from Johnson & Johnson, Novartis, and Pfizer Inc.; assisted in organizing the Pfizer Canada Inc. Advisory Board events; and speaking engagements (content not subject to sponsor approval)/honoraria from Pfizer Inc. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.